Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BNT162b2 Coadministered with Seasonal Inactivated Influenza Vaccine
NCT05310084Phase 3Completed
- Sponsor
- BioNTech SE
- Start
- Apr 2022
- Primary completion
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Started Apr 2022; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05310084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05310084.